ArticleFrontiers in endocrinology2024
The parathyroid glands identification of carbon nanoparticles via preoperative injection in reoperation of recurrent benign multinodular goiter.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Benign multinodular goiter (BMNG) can grow very large and cause compression symptoms, making the operation procedure difficult. However, the recurrence rate of BMNG ranges from 3% to 43%. Reoperative thyroid surgery for BMNG is uncommon and can result in a high rate of complications, including hypoparathyroidism and recurrent laryngeal nerve palsy. Carbon nanoparticles (CNs) have been widely used as a protective agent for the parathyroid gland and as a tracer agent in central lymph node dissection. However, the protection effect of CNs in redoing BMNG has not been well illustrated. This study investigates whether CNs could protect parathyroid glands (PGs) during reoperation for patients with BMNG. Methods: BMNG patients who previously underwent thyroidectomy and received reoperation between January 2019 and January 2022 were retrospectively recruited. The Dunhill approach was employed for all patients. The patients were divided into two groups: the CNs group, who received injection CNs injection 1 hour before the operation (n = 24), and the control group, who underwent thyroid surgery without CNs injection (control group, n = 25). The numbers of PGs preserved Results: The results revealed that more PGs were preserved
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.